← Back to RARE

Ultragenyx Pharmaceutical Inc. - Common Stock financial statements

Annual and standalone quarterly facts filed by the company with the SEC. Monetary values are shown in USD millions; per-share values use USD.

Filed statements

USD; millions except EPSJun 2026Filed 05/08/2026Mar 2026Filed 06/05/2026Sep 2025Filed 05/11/2025Jun 2025Filed 05/08/2026Mar 2025Filed 06/05/2026Sep 2024Filed 05/11/2025Jun 2024Filed 06/08/2025Mar 2024Filed 07/05/2025
$214$136$160$167$139$139$147$109
−$92−$185−$180−$115−$151−$134−$132−$171
−$0.90−$1.84−$1.81−$1.17−$1.57−$1.40−$1.52−$2.03
1021011009996958784

Trend

Revenue

Source: SEC EDGAR Company Facts. Values are normalized from issuer-filed US GAAP or IFRS XBRL facts. Missing cells stay missing; cumulative interim cash flows are not converted into estimated quarters.